OncoMatch/Clinical Trials/NCT06087614

Dose Escalation Using Hypoxia-adjusted Radiotherapy

Is NCT06087614 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cisplatin for head and neck squamous cell carcinoma.

Phase 2RecruitingRajiv Gandhi Cancer Institute & Research Center, IndiaNCT06087614Data as of May 2026

Treatment: Cisplatin — DE-HyART is a phase II clinical trial aimed at understanding the effects of escalating radiation doses to hypoxic sub-volumes inherent to squamous cell head and neck cancer. The study is aimed at assessing locoregional control, feasibility, and acceptable toxicity with such a strategy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Biomarker criteria

Excluded: CDKN2A p16 positive

HPV (p16) positive tumours [excluded]

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: surgery

Prior surgery and/or radiation therapy given for any HNC

Cannot have received: radiation therapy

Prior surgery and/or radiation therapy given for any HNC

Lab requirements

Blood counts

Hb: > 10g/dl (corrected); TLC: > 4,000 per cumm; Platelet: >1.5Lakh per cumm

Kidney function

Kidney functions within normal limits

Liver function

Liver functions within normal limits

Sufficient bone marrow reserve within the last 14 days. Hb: > 10g/dl (corrected); TLC: > 4,000 per cumm; Platelet: >1.5Lakh per cumm; Liver functions and kidney functions within normal limits

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify